Draig Therapeutics raised an additional $65 million in a Series B led by Deep Track Capital to advance DT-101, an AMPA receptor potentiator for major depressive disorder. The Cardiff University spinout said it can accelerate clinical execution as DT-101 progresses through Phase II studies and is preparing for broader late-stage testing. The financing arrives as the company positions AMPA modulation as an approach intended to recalibrate excitatory/inhibitory balance in depression—targeting a market with significant unmet need where response rates to first-line SSRIs remain limited. Draig also reported initiation activity across multiple studies, including global and U.S. monotherapy and adjunct evaluations. For biotech teams, the raise highlights continued investor appetite for mechanism-led neuropsychiatry assets that already have clinical traction, while emphasizing speed of execution and trial ramp-up capabilities.